AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A process for producing an antibody against a glypican protein comprising immunizing a ~~nonhuman animal~~ mouse with Fas function defects that develops autoimmune disease with a human glypican protein.

2. (Currently Amended) A process for producing an antibody against a glypican protein comprising immunizing an autoantibody-producing ~~nonhuman animal~~ mouse with Fas function defects with a human glypican protein.

3. - 4. (Canceled)

5. (Currently Amended) The process for producing an antibody against a glypican protein according to claim 1 or 2[[4]], wherein the mouse is the MRL/lpr mouse.

6. (Previously Presented) The process for producing an antibody against a glypican protein according to claim 1, wherein the glypican protein is glypican 3.

7. (Currently Amended) A process for producing an antibody comprising immunizing a ~~nonhuman animal~~ mouse with Fas function defects with a human native protein which has a sequence identity of 94% or more at the amino acid sequence level to a homolog protein of the ~~nonhuman animal~~ mouse to be immunized.

8. (Canceled)

9. (Currently Amended) The process for producing an antibody according to claim [[8]]] 7, wherein the mouse is the MRL/lpr mouse.

10-12. (Canceled)

13. (Currently Amended) The process of claim 1, wherein said ~~autoimuune~~ autoimmune disease is ~~selected from the group consisting of autoimmune hepatitis, autoimmune thyreoiditis, autoimmune bullous dermatosis, autoimmune inflammation of the adrenal cortex, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, autoimmune atrophic gastritis, autoimmune neutropenia, autoimmune orchitis, autoimmune encephalomyelitis, autoimmune receptor disease, autoimmune infertility, rheumatism, Crohn's disease,~~ systemic ~~erythematodes~~, erythematosous ~~multiple sclerosis, Basedow's disease, juvenile diabetes, Addison's disease, myasthenia gravis, and phacogenic uveitis~~.

14. (Previously Presented) The process of claim 7, wherein said Fas function defects comprises at least survival of B cells that respond to an autoantigen and produce an excess amount of autoantibody as compared to normally functional B cells.

15. (Withdrawn) The process of claim 7, wherein said Fas function defect is caused by a mutation in the Fas ligand gene.

16. (Currently Amended) The ~~mouse~~ process of claim 7[[8]], wherein said mouse has abnormal T cell accumulation as compared to a normal mouse, and wherein said mouse has a systemic erythematosous-like ~~erythematodes-like~~ autoimmune disease.

17. (Withdrawn-Currently Amended) The ~~mouse~~ process of claim 7[[8]], wherein said mouse is selected from the group consisting of a MRL/gld mouse, a MRL/Mp-+/+ mouse, a NZB/NZW F1 mouse, a BXSB/MpJ mouse, a B/WF1 mouse, a BXSB mouse and a SL/Ni mouse.

18. (Currently Amended) The ~~mouse~~ process of claim 7 [[8]], wherein said mouse is a mouse in which expression of Fas or Fas ligand is artificially repressed.

19. – 20. (Canceled).

21. (Currently Amended) The process of claim 1 or 2 [[3]], wherein said Fas function defects comprises at least survival of B cells that respond to an autoantigen and produce an excess amount of autoantibody when compared to normally functional B cells.

22. (Withdrawn-Currently Amended) The process of claim 1 or 2 [[3]], wherein said Fas function defect is caused by a mutation in the Fas ligand gene.

23. (Canceled)

24. (Withdrawn-Currently Amended) The ~~mouse~~ process of claim 1 or 2[[4]], wherein said mouse is selected from the group consisting of a MRL/gld mouse, a MRL/Mp-+/+ mouse, a NZB/NZW F1 mouse, a BXSB/MpJ mouse, a B/WF1 mouse, a BXSB mouse and a SL/Ni mouse.

25. (Canceled)